CRP and the Prognosis of Patients with Cirrhosis

The theory of vasodilation partially explains the development and progression of liver cirrhosis and is completed by the theory of inflammation. C-reactive protein (CRP) is used as a surrogate marker of inflammation in studies; however, there is not sufficient data that would reflect the role of this protein in cirrhosis yet. The objective of this study was to determine the use of CRP value in the prognosis of patients with cirrhosis. In "Material and method" section we described a clinical prospective trial with 102 participants represented by patients with cirrhosis of various etiologies in a tertiary hospital, each monitored throughout a period of 12 months after the collection of CRP. The results showed that the mean CRP value was 0.7+/0.09 mg/dL (CI 0.59-0.90) in patients who did not decompensate throughout the trial and 1.58+/0.4 mg/dL (CI 1.76-2.30) in those who did decompensate, with a statistically significant difference (p=0.045). In rehospitalized patients versus those without any hospitalization, the mean CRP values were 1.35 mg/dL and 0.8 mg/dL, respectively (p=0.032). The increased values of this parameter were positively correlated with the number of hospitalizations (rs=0.35, p=0.05). A CRP value below the threshold of 0.62 mg/dL indicates a smaller probability of future decompensation in liver cirrhosis patients. The conclusion of this study is that CRP influences the secondary endpoints, including cirrhosis decompensation and patient rehospitalization. It can be added to the existing studies.